Literature DB >> 1347916

Three distinct regions involved in 3p deletion in human lung cancer.

K Hibi1, T Takahashi, K Yamakawa, R Ueda, Y Sekido, Y Ariyoshi, M Suyama, H Takagi, Y Nakamura, T Takahashi.   

Abstract

The 3p deletion was first noted by cytogenetic analysis and was later confirmed by several independent studies using restriction fragment length polymorphism (RFLP) probes. As an initial step towards positional cloning (reverse genetics) of the tumor-suppressor gene(s) on 3p, a detailed analysis of the minimum deleted region(s) on 3p was performed with 13 RFLP probes and 48 paired human lung cancer samples. All nine small-cell lung cancer cases (100%) and 31 of 39 non-small-cell lung cancer cases (79%) showed allelic loss at one or more loci mapped on 3p. We show here that three distinct regions on 3p appear to be frequently deleted in lung cancer. These regions include 3p25, 3p21.3 and 3p14-cen. The present study should warrant future work focusing on these chromosomal regions on 3p, and may ultimately lead to the isolation of tumor-suppressor genes involved in the pathogenesis of lung cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347916

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

Review 1.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Quantitative fluorescence in situ hybridization in lung cancer as a diagnostic marker.

Authors:  K Truong; M Gerbault-Seureau; M N Guilly; P Vielh; G Zalcman; A Livartowski; A Chapelier; M F Poupon; B Dutrillaux; B Malfoy
Journal:  J Mol Diagn       Date:  1999-11       Impact factor: 5.568

Review 3.  8-Hydroxy-2'-deoxyguanosine as a marker of oxidative DNA damage related to occupational and environmental exposures.

Authors:  A Pilger; H W Rüdiger
Journal:  Int Arch Occup Environ Health       Date:  2006-05-10       Impact factor: 3.015

4.  Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer.

Authors:  S F Huang; S Xiao; A A Renshaw; K R Loughlin; T J Hudson; J A Fletcher
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

5.  Mapping of a new MAP kinase activated protein kinase gene (3PK) to human chromosome band 3p21.2 and ordering of 3PK and two cosmid markers in the 3p22-p21 tumour-suppressor region by two-colour fluorescence in situ hybridization.

Authors:  A Szeles; S Bajalica-Lagercrantz; A Lindblom; T Lushnikova; V I Kashuba; S Imreh; M Nordenskjöld; G Klein; E R Zabarovsky
Journal:  Chromosome Res       Date:  1996-06       Impact factor: 5.239

Review 6.  New prognostic factors in resectable non-small cell lung cancer.

Authors:  E F Smit; H J Groen; T A Splinter; T Ebels; P E Postmus
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

7.  Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck.

Authors:  M V González; M F Pello; P Ablanedo; C Suárez; V Alvarez; E Coto
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

Review 8.  Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis.

Authors:  V A Papadimitrakopoulou; D M Shin; W K Hong
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

9.  Linkage analysis and allelic imbalance in human breast cancer kindreds using microsatellite markers from the short arm of chromosome 3.

Authors:  J T Bergthorsson; G Eiriksdottir; R B Barkardottir; V Egilsson; A Arason; S Ingvarsson
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

10.  Allelic losses on chromosome 3p are accumulated in relation to morphological changes of lung adenocarcinoma.

Authors:  H Iijima; Y Tomizawa; K Dobashi; R Saito; T Nakajima; M Mori
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.